Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.

Trial Details

NCT ID
NCT04291105
Phase
PHASE2
Sponsor
Vyriad, Inc.
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • VV1
  • Cemiplimab
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Durate, California, United States
  • Los Angeles, California, United States|34.05223,-118.24368
  • Newport Beach, California, United States|33.61891,-117.92895
  • Santa Monica, California, United States|34.01949,-118.49138

Key Eligibility Criteria

  • Age ≥18 years on day of signing informed consent.
  • Specific by tumor cohorts:
  • a. For the HSNCC cohort, histologically confirmed diagnosis of advanced and/or metastatic HSNCC suitable for first line immunotherapy.
  • i. HPV+ and HPV- patients are allowed.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →